Sign up to save your podcasts
Or
Share Efgartigimod Builds a Pediatric Track Record in Myasthenia Gravis
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Efgartigimod Builds a Pediatric Track Record in Myasthenia Gravis
At AAN Annual Meeting 2026, efgartigimod alfa showed durable adolescent gMG responses, with 80% achieving minimal symptom expression by cycle two and consistent improvements across treatment cycles.
View all episodes
By TheBrief.HealthAt AAN Annual Meeting 2026, efgartigimod alfa showed durable adolescent gMG responses, with 80% achieving minimal symptom expression by cycle two and consistent improvements across treatment cycles.